PDCD1 and head and neck squamous cell carcinoma: Recently, the Keynote 048 trial showed that pembrolizumab, a mAb targeting programmed cell death 1 (PD1), as monotherapy improved survival over platinum/5-Fluorouracil (5-FU)/cetuximab in SCCHN patients with tumors expressing PD-L1.